AllianceBernstein’s Aldeyra Therapeutics ALDX Stock Holding History

AllianceBernstein’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-68,140	Closed	-$353K	–	3323
2026 Q1	$353K	Sell	68,140 -7,410	-10%	-$32.5K	﹤0.01%	2808
2025 Q4	$391K	Hold	75,550	–	–	﹤0.01%	2780
2025 Q3	$394K	Hold	75,550	–	–	﹤0.01%	2811
2025 Q2	$289K	Buy	75,550 +16,900	+29%	+$43.7K	﹤0.01%	2930
2025 Q1	$337K	Hold	58,650	–	–	﹤0.01%	2721
2024 Q4	$293K	Sell	58,650 -4,340	-7%	-$22.3K	﹤0.01%	2888
2024 Q3	$340K	Hold	62,990	–	–	﹤0.01%	2854
2024 Q2	$208K	Buy	62,990 +12,550	+25%	+$49.1K	﹤0.01%	3021
2024 Q1	$165K	Hold	50,440	–	–	﹤0.01%	2960
2023 Q4	$177K	Hold	50,440	–	–	﹤0.01%	3003
2023 Q3	$337K	Sell	50,440 -170,090	-77%	-$1.26M	﹤0.01%	2759
2023 Q2	$1.85M	Buy	+220,530	New	+$2.17M	﹤0.01%	1945
2022 Q1	–	Sell	-15,200	Closed	-$61K	–	3265
2021 Q4	$61K	Hold	15,200	–	–	﹤0.01%	3232
2021 Q3	$133K	Hold	15,200	–	–	﹤0.01%	3156
2021 Q2	$172K	Buy	+15,200	New	+$183K	﹤0.01%	3184
2020 Q2	–	Sell	-13,500	Closed	-$33K	–	3199
2020 Q1	$33K	Hold	13,500	–	–	﹤0.01%	3087
2019 Q4	$78K	Hold	13,500	–	–	﹤0.01%	3064
2019 Q3	$71K	Hold	13,500	–	–	﹤0.01%	3109
2019 Q2	$81K	Buy	+13,500	New	+$102K	﹤0.01%	3104

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

AllianceBernstein's ALDX Position: Q2 2026 in Review

AllianceBernstein sold out of Aldeyra Therapeutics (ALDX) in Q2 2026, closing a stake of 68,140 shares — an estimated $353K sold.

AllianceBernstein first reported a position in ALDX in Q2 2019 and held it in 19 quarters. The position peaked at $1.85M in Q2 2023. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

AllianceBernstein reported no remaining Aldeyra Therapeutics position as of Q2 2026 after selling out during the quarter.
AllianceBernstein sold 68,140 Aldeyra Therapeutics shares in Q2 2026, an estimated $353K.
AllianceBernstein first reported a position in Aldeyra Therapeutics in Q2 2019 and held it in 19 quarters.
AllianceBernstein's Aldeyra Therapeutics position peaked at $1.85M in Q2 2023.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.